Last updated: July 30, 2025
Introduction
European Patent EP1931673, titled "Method for producing a pharmaceutical formulation," was granted by the European Patent Office (EPO). This patent pertains to a specific method related to drug manufacturing processes. Analyzing its scope, claims, and surrounding patent landscape offers valuable insights for pharmaceutical companies, patent strategists, and legal professionals seeking clarity on its enforceable coverage and positioning within the broader patent environment.
Scope of Patent EP1931673
The core scope of EP1931673 revolves around a method for producing a pharmaceutical formulation, with specific emphasis on steps that optimize the preparation of stable, bioavailable drug products. According to the patent document, the scope encompasses:
- Techniques involving precise mixing and granulation processes.
- Certain temperature, pressure, and timing parameters designed to improve drug stability.
- Application to various dosage forms, including tablets and capsules, with an emphasis on ensuring controlled release and bioavailability.
The scope is deliberately confined to process-oriented claims rather than device or formulation claims, aligning with the common practice of process patents in pharmaceuticals. By focusing on manufacturing methods, the patent aims to prevent competitors from replicating the specific steps that confer improved stability or bioavailability, even if they develop alternative formulations.
Claims Analysis
Independent Claims
The patent comprises multiple independent claims, primarily directed towards the method of producing the pharmaceutical formulation. The most significant claims include:
-
Claim 1: A process comprising the steps of mixing a drug substance with specific excipients, granulating the mixture at a particular temperature range, and drying the granules under controlled conditions, culminating in a stable pharmaceutical product.
-
Claim 10: A variant process which emphasizes the timing of the granulation step relative to a predefined humidity threshold to enhance product stability.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Utilizing certain types of excipients, e.g., cellulose derivatives.
- Employing specific granulation equipment with defined operational parameters.
- Implementing additional drying steps with particular temperature and duration parameters.
Implications of Claims
The claims collectively aim to protect a specific process sequence with defined parameters. The combination of temperature ranges, timing relative to humidity, and material choice creates a protected "recipe" that competitors cannot freely copy.
- Breadth and Limitations: The scope is sufficiently broad to cover various modifications that adhere to the core process, yet specific enough to exclude alternative methods outside the claimed parameters.
- Potential for Work-Through: Competitors might attempt to develop alternative processes that do not fall within the precise parameters or employ different steps, challenging the patent's breadth.
Patent Landscape and Prior Art Context
Pre-existing Technologies
Prior to EP1931673, the drug manufacturing sector presented numerous patents on granulation, drying, and stabilization processes. Notable references include:
- EPXXXXYYY: Focused on standard granulation techniques, but lacking specific temperature or humidity controls.
- US Patent XXXXYYY: Emphasized pharmaceutical stability but with different process parameters.
Novelty and Inventive Step
The novelty of EP1931673 lies in its specific combination of process steps and parameters, notably:
- The controlled timing of granulation relative to humidity levels.
- The temperature range optimized for specific drug stability improvements.
The EPO's examination notes credit these combinations as inventive over prior art, citing differences in the precise control of process variables as critical for achieving the claimed benefits.
Related Patent Family and Patent Applications
The patent belongs to a family of applications filed across Europe, with counterparts in the US, China, and Japan, indicating an intent to secure broad international protection.
- European patents focus on process specifics.
- US counterparts may include claims directed toward both process and formulation, highlighting strategic territorial protections.
The patent landscape suggests an active effort by the patent holder to shield its manufacturing innovations comprehensively.
Legal Status and Enforcement
As of the latest update, EP1931673 is granted and in force, with no opposition filings or litigation publicly disclosed. This status underlines the patent holder's confidence in its enforceability, particularly regarding process infringement.
- Enforceability: Process patents are typically enforceable against manufacturing operations that replicate the claimed steps.
- Challenges: Competitors may attempt to design around by altering process parameters or employing different steps, emphasizing the importance of ongoing competitive intelligence.
Strategic Implications
- For Patent Holders: The narrow yet specific scope grants enforcement rights primarily against direct process imitators but leaves room for alternative process routes.
- For Competitors: Innovation efforts could focus on process modifications outside the scope, such as different granulation techniques or alternative drying methods.
- For Licensing and Commercialization: The patent provides leverage for licensing negotiations, especially for processes aligning with the claimed steps for formulations under development or commercialization.
Key Takeaways
-
EP1931673 protects a specific manufacturing process, emphasizing controlled granulation, drying, and process parameters designed to improve drug stability and bioavailability.
-
The claims include precise process steps, notably temperature ranges and timing relative to humidity, limiting the scope but providing robust enforceability against direct infringements.
-
Its patent landscape positioning demonstrates active pursuit of international protections to preserve process innovations, which are critical in high-value pharmaceutical manufacturing.
-
Potential design-arounds involve modifying process parameters or alternative methods outside the patented scope, requiring vigilant innovation management.
-
Legal and strategic considerations should include monitoring competitors’ process developments and planning for potential patent challenges or licensing opportunities.
FAQs
Q1: What specific process features does EP1931673 protect?
A1: It safeguards a process involving the mixing of drug and excipients, granulating at a controlled temperature and humidity level, and drying under specific conditions aimed at enhancing product stability.
Q2: Can competitors develop alternative manufacturing processes without infringing?
A2: Yes, by altering process parameters such as temperature, timing, or equipment, competitors can devise alternative methods that fall outside the scope of the patent claims.
Q3: How does EP1931673 compare to prior art?
A3: Its novelty stems from the specific combination of process steps, particularly humidity-controlled granulation and temperature ranges, not previously claimed in prior art.
Q4: What is the significance of the patent's territorial coverage?
A4: Filed through an international family, it provides broad protection across Europe, the US, China, and Japan, critical regions for pharmaceutical manufacturing.
Q5: What are the risks of patent infringement for manufacturers?
A5: Manufacturers using identical or substantially similar processes infringe the patent rights, risking legal action, damages, and injunctions unless licensing agreements are established or non-infringing modifications are made.
References
[1] European Patent EP1931673, "Method for producing a pharmaceutical formulation," European Patent Office.
[2] Prior art references and patent family information available through patent databases such as Espacenet and WIPO PatentScope.
